News und Analysen
Could Vertex Pharmaceuticals Stock Help You Become a Millionaire?
Biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) has made for a solid investment over the past decade, more than quadrupling in value during that period. The stock generated fantastic returns
Want Rising Dividend Income? Buy Amgen Stock
The cost of living is getting more and more expensive. This is because inflation steadily diminishes the value of the U.S. dollar over time, and the purchasing power of said dollar as a result.
One
3 Top Biotech Stocks Defying the Bear Market
If you look at the S&P 500, which is up more than 18% this year, or the Nasdaq Composite, which is up more than 34% in 2023, it appears the markets are booming. If you look specifically at biotech
MacroGenics (MGNX) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
MacroGenics (NASDAQ: MGNX)Q2 2023 Earnings CallAug 09, 2023, 4:30 p.m. ET
Operator
Source Fool.com
2 Supercharged Growth Stocks That Could Make You Richer
If you're looking for stocks that can deliver better-than-average returns in the long run, you might want to consider these two biotechs: Exact Sciences (NASDAQ: EXAS) and Vertex Pharmaceuticals
Why Shares of BioLife Solutions Are Slumping on Wednesday
Shares of BioLife Solutions (NASDAQ: BLFS) were down by more than 27% as of 1:15 p.m. on Wednesday after the healthcare company posted its second-quarter earnings report. The stock is down more than
Why Shares of Mirati Therapeutics Are Jumping Wednesday
Shares of Mirati Therapeutics (NASDAQ: MRTX) are up more than 27% as of 10:25 a.m. ET. The company released earnings after the markets closed on Tuesday. The healthcare stock is down more than 21%
3 Stocks That Recently Raised Their Guidance for the Year
GDP grew at a rate of 2.4% in the second quarter as the economy did better than expected. And many businesses are also seeing strong demand for their products and services. That, in turn, leads to
More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection
Alzheimer's patients could soon have more treatment options available. Biogen's Leqembi obtained approval from the U.S. Food and Drug Administration earlier this year, and another treatment from Eli
Pfizer's Profits Plunge 77%: Is the Dividend Still Safe?
Pfizer (NYSE: PFE) provides investors with an attractive dividend that currently yields 4.7%. To collect $1,000 in annual dividends at that rate, you would need to invest approximately $21,300
Investing $1,000 in These 2 Top Stocks Would Be a Brilliant Move
One of the great things about investing in stocks is that there is no need to have millions in the bank to get started. A relatively modest sum such as $1,000 can go a long way if invested shrewdly
With an Acquisition on the Way, Is Biogen Stock a Buy?
Biotech giant Biogen (NASDAQ: BIIB) can't seem to keep its name out of the news. After a recent major approval for its Alzheimer's disease (AD) medicine Leqembi, the company just announced that it
STAAR Surgical Teams Up With Tennessee Titans Quarterback Will Levis On Life Changing Vision Correction Procedure, EVO ICL
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced its partnership with Will Levis, quarterback for the
Is Vertex Pharmaceuticals Stock a Buy Now?
As one of the hottest and most-watched companies in the biopharmaceutical sector, Vertex Pharmaceuticals (NASDAQ: VRTX) has a unique mix of stability and growth potential that's attractive to a
Is This MedTech Giant a Buy for Dividend Investors?
Buying industry-leading companies in industries with growth potential tends to produce delightful results for dividend investors. This is because such businesses can generate revenue and earnings
Invitae (NVTA) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Invitae (NYSE: NVTA)Q2 2023 Earnings CallAug 08, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Why MannKind Stock Soared 19% Higher on Tuesday
Commercial-stage biotech MannKind (NASDAQ: MNKD) was a top choice of investors on the second day of the trading week. Tuesday saw MannKind's share price leap by almost 19%, making it stand out on a
CorMedix (CRMD) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
CorMedix (NASDAQ: CRMD)Q2 2023 Earnings CallAug 08, 2023, 8:30 a.m. ET
Operator
Source Fool.com
Why Novocure Was a Healthy Stock Today
Cancer-focused biotech Novocure (NASDAQ: NVCR) was the focus of an analyst upgrade on Tuesday, and the stock benefited from the move. In late-session trading that day, it was up by more than 3.3% in
Zoetis (ZTS) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Zoetis (NYSE: ZTS)Q2 2023 Earnings CallAug 08, 2023, 8:30 a.m. ET
Operator
Source Fool.com
Why Shares of Enanta Pharmaceuticals Are Dropping Tuesday
Shares of Enanta Pharmaceuticals (NASDAQ: ENTA) were down more than 9% as of 11:45 a.m. on Tuesday after the clinical-stage biotech released fiscal third-quarter earnings on Tuesday. The stock is
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Are On Fire Today
Weight loss drugmakers are having an exceptionally strong trading session today. As of 10:32 a.m. ET Tuesday morning, Eli Lilly (NYSE: LLY) was up by a noteworthy 16.7%, Novo Nordisk (NYSE: NVO) was
Is Sage Therapeutics a Contrarian Buy?
Monday was a dark day for Sage Therapeutics (NASDAQ: SAGE), a company that focuses on developing therapies for brain disorders. The stock plummeted by more than 53% after the company revealed that
Is AbbVie Still a Good Dividend Stock to Buy?
How do you know when a former favorite dividend stock is no longer one you should buy, or hold? Some would say it's time to look away as soon as the profits the company uses to make dividend
2 High-Yield Dividend Stocks to Buy on the Dip
Income-seeking investors tend to be drawn to high dividend yields. The higher the yield, the better a dividend becomes at generating income that can fund an investor's spending as well as beat